Study Evaluating Venetoclax in Subjects With Hematological Malignancies
- Conditions
- Chronic Lymphocytic Leukemia (CLL)Non-Hodgkin Lymphoma (NHL)Multiple Myeloma (MM)Small Lymphocytic Lymphoma (SLL)Acute Myeloid Leukemia (AML)
- Interventions
- Registration Number
- NCT02265731
- Lead Sponsor
- AbbVie
- Brief Summary
This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
- Participants must have histologically documented diagnosis of NHL (and exhausted options considered standard of care) as defined in the World Health Organization classification scheme and relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens. Participants with other lymphoproliferative diseases can be considered in consultation with the AbbVie medical monitor
- Relapsed or refractory multiple myeloma participants must have been previously treated with at least one prior line of therapy and have measurable disease
- Chronic lymphocytic leukemia/small lymphocytic lymphoma participants must have relapsed or be refractory to standard treatments such as fludarabine based regimens or alkylator based regimens
- Untreated AML subjects or Relapsed or refractory AML subjects must have been previously treated with at least one prior line of therapy
- Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 1; adequate bone marrow independent of growth factor support per local laboratory reference range; and adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening
- Participants with a history of autologous or allogenic stem cell transplantation must have adequate blood counts independent of growth factor support and have recovered from any transplant-related toxicity(s) and be at least 100 days post-autologous transplant (multiple myeloma) or 6 month post-autologous transplant (NHL) prior to first dose of study drug or at least 6 months post-allogenic transplant (multiple myeloma) prior to first dose of study drug and not have active graft-versus-host disease (GVHD), i.e., requiring treatment
- NHL participants who have undergone an allogeneic stem cell transplant or were diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia
- Participant tested positive for HIV
- Participant has a cardiovascular disability status of New York Heart Association Class greater or equal to 2
- Participant has a significant history of renal, neurologic, psychiatric, pulmonary, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the Investigator would adversely affect his/her participating in this study.
- Participant received a monoclonal antibody for anti-neoplastic intent within 8 weeks prior to the first dose of study drug.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Arm A (Phase 1) venetoclax Step-up doses of venetoclax to the designated cohort dose administered in participants with relapsed or refractory (R/R) Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) Arm B (Phase 1) venetoclax Step-up doses of venetoclax to the designated dose administered in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Arm C (Phase 1) azacitadine Step-up doses of venetoclax to the designated dose with the addition of azacitidine administered in participants with acute myeloid leukemia (AML) Arm C (Phase 1) venetoclax Step-up doses of venetoclax to the designated dose with the addition of azacitidine administered in participants with acute myeloid leukemia (AML) Arm D (Phase 2) rituximab / IDEC-C2B8 Step-up doses of venetoclax to the designated dose with the addition of rituximab in participants with R/R CLL Arm D (Phase 2) venetoclax Step-up doses of venetoclax to the designated dose with the addition of rituximab in participants with R/R CLL
- Primary Outcome Measures
Name Time Method Time to maximum plasma concentration (Tmax) of venetoclax Approximately 8 days Number of participants having treatment-emergent adverse events Approximately 2 years Collect all adverse events at each visit
Maximum plasma concentration (Cmax) of venetoclax Approximately 8 days Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax Approximately 8 days Objective Response Rate (Phase 2) Approximately 48 months The proportion of participants with response (e.g., partial, complete response) using IWCLL (International Workshop on Chronic Lymphocytic Leukemia) criteria for CLL participants will be computed for all participants with active disease at baseline (in the opinion of the investigator).
- Secondary Outcome Measures
Name Time Method Objective Response Rate (Phase 1) Approximately 48 months The proportion of participants with response (e.g., partial, complete response) using IWG (International Working Group) response criteria for NHL participants, IMWG (International Myeloma Working Group) response criteria for multiple myeloma participants, IWCLL (International Workshop on Chronic Lymphocytic Leukemia) criteria for CLL participants or IWG (International Working Group) criteria for AML participants will be computed for all participants with active disease at baseline (in the opinion of the investigator).
Minimal Residual Disease (MRD) Approximately 2 years Duration of Response Approximately 48 months Duration of response is defined as the number of days from the participant's initial response (e.g., partial, complete response per disease-appropriate response criteria) to the day that disease progression is objectively documented.
Time to disease progression Approximately 48 months Time to disease progression is defined as the number of days from the date the subject started the study drug to the date of the subject's progression (all events of progression will be included).
complete response or remission (CR) rate Approximately 48 months CR rate will be defined as the proportion of participants who achieved a complete response or remission (CR) or complete response with incomplete bone marrow recovery or complete remission with incomplete count recovery (CRi) per the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria.
Partial response or remission (PR) rate Approximately 48 months PR rate will be defined as the proportion of subjects who achieved a nodular PR (nPR) or PR per the 2008 IWCLL criteria.
Progression Free Survival (PFS) Approximately 48 months Duration of progression-free survival (PFS) will be defined as the number of days from the date of first dose to the date of earliest disease progression or death.
Trial Locations
- Locations (14)
Nagoya City University Hospital /ID# 129278
🇯🇵Nagoya shi, Aichi, Japan
NHO Nagoya Medical Center /ID# 129222
🇯🇵Nagoya-shi, Aichi, Japan
Osaka University Hospital /ID# 169862
🇯🇵Suita-shi, Osaka, Japan
Aichi Cancer Center Hospital /ID# 129061
🇯🇵Nagoya-shi, Aichi, Japan
National Hospital Organization Kyushu Cancer Center /ID# 149741
🇯🇵Fukuoka-shi, Fukuoka, Japan
Kyushu University Hospital /ID# 163202
🇯🇵Fukuoka-shi, Fukuoka, Japan
Kindai University Hospital /ID# 169554
🇯🇵Osakasayama-shi, Osaka, Japan
The Cancer Institute Hospital Of JFCR /ID# 129277
🇯🇵Koto-ku, Tokyo, Japan
NTT Medical Center Tokyo /ID# 166281
🇯🇵Shinagawa-ku, Tokyo, Japan
Kobe City Medical Center General Hospital /ID# 170919
🇯🇵Kobe-shi, Hyogo, Japan
National Cancer Center Hospital /ID# 129044
🇯🇵Chuo-ku, Tokyo, Japan
Toranomon Hospital /ID# 148229
🇯🇵Minato-ku, Tokyo, Japan
University of Fukui Hospital /ID# 165801
🇯🇵Yoshida-gun, Fukui, Japan
Tohoku University Hospital /ID# 129275
🇯🇵Sendai-shi, Miyagi, Japan